Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Antidepressants vs placebo · Efficacy as a dichotomous outcome
  Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
  RR 0.74 [0.57, 0.96]
  7 studies · 662 participants
  Very low
Direct match · question page
- Selective serotonin reuptake inhibitors (SSRIs) vs tricyclic antidepressants (TCAs) · Efficacy as a dichotomous outcome
  Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
  RR 1.1
  2 studies · 199 participants
  Very low
Direct match · question page
- Mirtazapine vs tricyclic antidepressants (TCA) · Efficacy as a dichotomous outcome
  Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
  RR 0.81 [0.6, 1.09]
  1 study · 33 participants
  Very low

Antidepressants vs placebo

Efficacy as a dichotomous outcome · adults with cancer and depression

It is very uncertain whether antidepressants changes efficacy as a dichotomous outcome compared with placebo (very low certainty).

1 finding from 1 review

Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
RR 0.74 [0.57, 0.96]
7 studies · 662 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Efficacy as a dichotomous outcome · patients with cancer and depression

It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes efficacy as a dichotomous outcome compared with tricyclic antidepressants (TCAs) (very low certainty).

1 finding from 1 review

Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
RR 1.1
2 studies · 199 participants
Very low

Mirtazapine vs tricyclic antidepressants (TCAs)

Efficacy as a dichotomous outcome · adults with cancer and depression

It is very uncertain whether mirtazapine changes efficacy as a dichotomous outcome compared with tricyclic antidepressants (TCA) (very low certainty).

1 finding from 1 review

Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
RR 0.81 [0.6, 1.09]
1 study · 33 participants
Very low